To further investigate the effect of CD2‐deficient CTLs on BCBM, we established both subcutaneous and brain metastasis models in mice to evaluate their impact on primary tumor growth and metastatic progression (Figure 5A). The gene discussed is CD2; the disease is neoplasm.